Iveda files prospectus to register 5.26M shares

Iveda Solutions, Inc. registers primary securities for sale.

Rhea-AI Filing Summary

Iveda Solutions, Inc. registers primary securities for sale. The prospectus supplement registers 5,259,999 shares of Common Stock, up to 5,714,286 Series X Warrants to purchase up to 11,428,572 shares of Common Stock, and up to 400,000 Placement Agent Warrants to purchase up to 400,000 shares. The supplement incorporates the company's Form 10-K for the period ended December 31, 2025 and updates the Prospectus effective February 9, 2026.

Key Figures

Registered common stock: 5,259,999 shares Series X Warrants registered: 5,714,286 warrants Placement Agent Warrants: 400,000 warrants +1 more

4 metrics

Registered common stock 5,259,999 shares Prospectus Supplement No. 1

Series X Warrants registered 5,714,286 warrants each exercisable into 2 shares for up to 11,428,572 shares

Placement Agent Warrants 400,000 warrants exercisable into up to 400,000 shares

Form 10-K referenced Form 10-K for period ended December 31, 2025 attached to the Prospectus Supplement

Key Terms

Prospectus Supplement, Series X Warrants, Placement Agent Warrants

3 terms

Prospectus Supplement regulatory

"This Prospectus Supplement supplements and amends the Prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Series X Warrants financial

"up to 5,714,286 Series X Warrants to purchase up to 11,428,572 Shares"

Series X warrants are a specific class (or tranche) of warrants — financial instruments that give the holder the right, but not the obligation, to buy a set number of a company's shares at a predetermined price before a fixed expiry date. They matter to investors because exercising them can dilute existing shareholdings and signal potential future capital raising, while offering holders leveraged upside if the stock rises above the strike price, similar to a coupon that lets you buy a concert ticket at today’s price even if ticket prices climb later.

Placement Agent Warrants financial

"up to 400,000 Placement Agent Warrants to purchase up to 400,000 Shares"

Placement agent warrants are options given to the broker or intermediary who helps a company sell shares privately; they grant the holder the right to buy a set number of company shares at a fixed price in the future. For investors, these warrants matter because exercising them increases the total shares outstanding and can dilute existing ownership and earnings per share, similar to adding more slices to a pizza and reducing the size of each existing slice.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What securities did Iveda Solutions (IVDA) register in this prospectus supplement?

The company registered 5,259,999 shares of Common Stock and related warrants. The supplement also registers up to 5,714,286 Series X Warrants (exercisable into 11,428,572 shares) and up to 400,000 Placement Agent Warrants exercisable into 400,000 shares.

Does the supplement reference recent financial filings for Iveda Solutions (IVDA)?

Yes. The supplement incorporates the Form 10-K for the period ended December 31, 2025. The Form 10-K filed March 31, 2026 is attached to the supplement and updates the Prospectus where specified.

Are the exercise amounts for the Series X Warrants specified in the supplement?

Yes. The Series X Warrants are registered to purchase up to 11,428,572 shares of Common Stock. The supplement states there are up to 5,714,286 Series X Warrants, each exercisable into two shares as described.

How many placement agent warrants were registered by Iveda Solutions (IVDA)?

The supplement registers up to 400,000 Placement Agent Warrants. Each Placement Agent Warrant is exercisable into one share, for a total potential of 400,000 shares from those warrants.

When is this Prospectus Supplement dated and which prospectus does it amend?

The Prospectus Supplement is dated April 1, 2026 and amends the Prospectus effective February 9, 2026. It supplements the Prospectus dated February 4, 2026 and is qualified by that Prospectus except where it updates or supersedes information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 06:38 PM EDT Learn about SEC filing dates

Prospectus Supplement No. 1	Filed Pursuant to Rule 424(b)(3)
(To Prospectus effective February 9, 2026)	Registration No. 333-293126

5,259,999 Shares of Common Stock

Up to 5,714,286 Series X Warrants to purchase up to 11,428,572 Shares of Common Stock

Up to 400,000 Placement Agent Warrants to purchase up to 400,000 Shares of Common Stock

This Prospectus Supplement supplements and amends the Prospectus dated February 4, 2026 and effective February 9, 2026 (the “Prospectus”), relating to the purchase of 5,259,999 shares of common stock (the “Common Stock”), up to 5,714,286 series x warrants to purchase up to 11,428,572 shares of Common Stock (the “Series X Warrants”), and up to 400,000 placement agent warrants to purchase up to 400,000 shares of Common Stock (the “Placement Agent Warrants”) of Iveda Solutions, Inc. (the “Company”).

This Prospectus Supplement is being filed to include the information set forth in our Annual Report on Form 10-K for the period ended December 31, 2025, filed by the Company with the Securities and Exchange Commission on March 31, 2026 (the “Form 10-K”). The Form 10-K is attached hereto.

This Prospectus Supplement is not complete without and may not be delivered or utilized except in connection with the Prospectus, including any supplements and amendments thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, which is to be delivered with this Prospectus Supplement. This Prospectus Supplement is qualified by reference to the Prospectus, except to the extent that the information in this Prospectus Supplement updates or supersedes the information contained in the Prospectus, including any supplements and amendments thereto.

See “Risk Factors” beginning on page 11 of the Prospectus to read about factors you should consider before buying shares of our common stock.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of the Prospectus. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement is April 1, 2026